New peer-reviewed study highlights safety and clinical benefits of intradiscal MSC therapy for chronic low back pain ...
NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Rising demand for mesenchymal stem cell (MSC)-based therapies, coupled with expanding applications in regenerative medicine, immunotherapy, and tissue ...
MSCs improve therapeutic consistency and precision across cell therapies. The approach also supports scalable allogeneic ...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a patented ...
Mesoblast offers asymmetric risk-reward with Ryoncil's rapid pediatric SR-aGvHD launch and multiple late-stage pipeline catalysts. Learn why MESO stock is a hold.
Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.
A new way of using umbilical cord blood for treating blood diseases could make the treatment more accessible to patients who ...
A stem cell therapy with potential disease-modifying effects for feline osteoarthritis (OA) is underway. Gallant, an animal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results